

UNITED STATES SECURITIES AND EXCHANGE
COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden

hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>HUFNAGEL CHRISTOPER</u>			2. Date of Event Requiring Statement (Month/Day/Year) 04/29/2020		3. Issuer Name and Ticker or Trading Symbol <u>WOLVERINE WORLD WIDE INC /DE/ [www]</u>		
(Last)	(First)	(Middle)	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> Officer (give title below) President, Merrell			5. If Amendment, Date of Original Filed (Month/Day/Year)	
C/O 9341 COURTLAND DRIVE NE			10% Owner			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person	
(Street) ROCKFORD MI 49351			Other (specify below)			Form filed by More than One Reporting Person	
(City) (State) (Zip)							

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	64,199 ⁽¹⁾	D	

Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Options (Right to Buy) ⁽²⁾	02/09/2012 ⁽³⁾	02/08/2021	Common Stock	12,300	18.25	D	
Stock Options (Right to Buy) ⁽²⁾	02/08/2013 ⁽⁴⁾	02/07/2022	Common Stock	18,000	19.92	D	
Stock Options (Right to Buy) ⁽²⁾	02/06/2014 ⁽⁵⁾	02/05/2023	Common Stock	19,420	21.48	D	
Stock Options (Right to Buy)	02/11/2015 ⁽⁶⁾	02/10/2024	Common Stock	17,022	27.13	D	
Stock Options (Right to Buy)	02/11/2016 ⁽⁷⁾	02/10/2025	Common Stock	16,789	28	D	
Stock Options (Right to Buy)	02/10/2017 ⁽⁸⁾	02/09/2026	Common Stock	32,294	16.51	D	
Restricted Stock Units	(9)	(9)	Common Stock	2,246	0.00 ⁽¹⁰⁾	D	
Restricted Stock Units	(11)	(11)	Common Stock	3,203	0.00 ⁽¹⁰⁾	D	
Restricted Stock Units	(12)	(12)	Common Stock	3,908	0.00 ⁽¹⁰⁾	D	
Restricted Stock Units	(13)	(13)	Common Stock	1,500	0.00 ⁽¹⁰⁾	D	
Restricted Stock Units	(14)	(14)	Common Stock	1,000	0.00 ⁽¹⁰⁾	D	
Restricted Stock Units	(15)	(15)	Common Stock	5,176	0.00 ⁽¹⁰⁾	D	
Restricted Stock Units	(16)	(16)	Common Stock	3,855	0.00 ⁽¹⁰⁾	D	
Restricted Stock Units	(17)	(17)	Common Stock	5,783	0.00 ⁽¹⁰⁾	D	

Explanation of Responses:

- The number of shares reported includes 7,297 time-vested restricted shares of Common Stock granted to the Reporting Person on various dates from December 2015 to February 2016, under both the Company's Stock Incentive Plan of 2013 and Stock Incentive Plan of 2016.
- The number of shares and exercise price have been adjusted to reflect the Company's November 1, 2013 two-for-one stock split.
- This option became exercisable as to 4,100 shares on February 9, 2012, as to 4,100 shares on February 9, 2013, and as to 4,100 shares on February 9, 2014.
- This option became exercisable as to 6,000 shares on February 8, 2013, as to 6,000 shares on February 8, 2014, and as to 6,000 shares on February 8, 2015.
- This option became exercisable as to 6,474 shares on February 6, 2014, as to 6,473 shares on February 6, 2015, and as to 6,473 shares on February 6, 2016.

6. This option became exercisable as to 5,674 shares on February 11, 2015, as to 5,674 shares on February 11, 2016, and as to 5,674 shares on February 11, 2017.
7. This option became exercisable as to 5,597 shares on February 11, 2016, as to 5,596 shares on February 11, 2017, and as to 5,596 shares on February 11, 2018.
8. This option became exercisable as to 10,765 shares on February 10, 2017, as to 10,764 shares on February 10, 2018, and as to 10,765 shares on February 10, 2019.
9. On February 8, 2017, the Reporting Person was granted 7,486 restricted stock units, vesting as follows, subject to the Reporting Person's continued employment: 20%, 20%, 30% and 30% on each of the first, second, third and fourth year anniversaries of the grant date, respectively. The restricted stock units have no expiration date.
10. Restricted stock units convert into shares of Common Stock on a one-for-one basis.
11. On February 7, 2018, the Reporting Person was granted 5,338 restricted stock units, vesting as follows, subject to the Reporting Person's continued employment: 20%, 20%, 30% and 30% on each of the first, second, third and fourth year anniversaries of the grant date, respectively. The restricted stock units have no expiration date.
12. On February 6, 2019, the Reporting Person was granted 4,884 restricted stock units, vesting as follows, subject to the Reporting Person's continued employment: 20%, 20%, 30% and 30% on each of the first, second, third and fourth year anniversaries of the grant date, respectively. The restricted stock units have no expiration date.
13. On October 28, 2019, the Reporting Person was granted 1,500 restricted stock units, vesting 50% on each of the first and second year anniversaries of the grant date, subject to the Reporting Person's continued employment. The restricted stock units have no expiration date.
14. On January 27, 2020, the Reporting Person was granted 1,000 restricted stock units, vesting 100% on the first anniversary of the grant date, subject to the Reporting Person's continued employment. The restricted stock units have no expiration date.
15. On February 5, 2020, the Reporting Person was granted 5,176 restricted stock units, vesting as follows, subject to the Reporting Person's continued employment: 20%, 20%, 30% and 30% on each of the first, second, third and fourth year anniversaries of the grant date, respectively. The restricted stock units have no expiration date.
16. On April 17, 2020, the Reporting Person was granted 3,855 restricted stock units, vesting 100% on the first anniversary of the grant date, subject to the Reporting Person's continued employment. The restricted stock units have no expiration date.
17. On April 17, 2020, the Reporting Person was granted 5,783 restricted stock units, vesting 100% on December 23, 2020, subject to the Reporting Person's continued employment. The restricted stock units have no expiration date.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

<u>/s/ David Latchana, by</u> <u>Power of Attorney</u>	<u>05/01/2020</u>
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Exhibit 24
LIMITED POWER OF ATTORNEY

The undersigned, a director and/or officer of Wolverine World Wide, Inc., a Delaware corporation ("Wolverine"), does hereby appoint KYLE L. HANSON and DAVID A. LATCHANA, or any one or more of them, with full power of substitution, his or her attorneys and agents to do any and all acts and things and to execute and file any and all documents and instruments that such attorneys and agents, or any of them, consider necessary or advisable to enable the undersigned (in his or her individual capacity or in a fiduciary or other capacity) to comply with the Securities Act of 1933, as amended (the "Securities Act"), and the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and any requirements of the Securities and Exchange Commission in respect thereof, in connection with his or her intended sale of any security related to Wolverine pursuant to Rule 144 issued under the Securities Act and the preparation, execution and filing of any report or statement of beneficial ownership or changes in beneficial ownership of securities of Wolverine that the undersigned (in his or her individual capacity or in a fiduciary or other capacity) may be required to file pursuant to Section 16(a) of the Exchange Act including, without limitation, full power and authority to sign the undersigned's name, in his or her individual capacity or in a fiduciary or other capacity, to any report or statement on Form 3, 4, 5 or 144, or to any amendments or any successor forms thereto, or any form or forms adopted by the Securities and Exchange Commission in lieu thereof or in addition thereto, hereby ratifying and confirming all that such attorneys and agents, or any of them, shall do or cause to be done by virtue hereof.

The undersigned agrees that the attorneys-in-fact act as legal counsel to and/or officers of Wolverine in connection with the securities matters addressed herein, and do not represent the undersigned in his or her personal capacity in connection with such matters. The undersigned agrees that the attorneys-in-fact may rely entirely on information furnished orally or in writing by the undersigned or his or her authorized representative(s) to such attorneys-in-fact. The undersigned also agrees to indemnify and hold harmless Wolverine and the attorneys-in-fact against any losses, claims, damages or liabilities (or actions in respect thereof) that arise out of or are based upon any untrue statement or omission of necessary fact in the information provided by the undersigned or his or her authorized representative(s) to the attorneys-in-fact for purposes of executing, acknowledging, delivering or filing any such forms, or any amendments or any successor forms thereto, or any form or forms adopted by the Securities and Exchange Commission in lieu thereof or in addition thereto. The undersigned agrees to reimburse Wolverine and the attorneys-in-fact for any legal or other expenses reasonably incurred in connection with investigating or defending against any such loss, claim, damage, liability or action.

This authorization shall supersede all prior authorizations to act for the undersigned with respect to securities of Wolverine in these matters, which prior authorizations are hereby revoked, and shall survive the termination of the undersigned's status as a director and/or officer of Wolverine and remain in effect thereafter for so long as the undersigned (in his or her individual capacity or in a fiduciary or other capacity) is subject to Rule 144 with respect to securities of Wolverine or has any obligation under Section 16 of the Exchange Act with respect to securities of Wolverine.

Date: April 30, 2020

/s/ Christopher Hufnagel

(Signature)

Christopher Hufnagel

(Name)